Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

der cancer drug, VALSTAR®.    

Reported or GAAP earnings reflect a net pre-tax gain of $60 million related to purchase accounting considerations associated with AVEED™, our injectable testosterone product, currently in registration with the FDA.  As previously announced, in December, we received a complete response letter from the FDA with respect to our NDA for this product.  This letter, in turn, triggered a review for asset impairment.  Significant regulatory uncertainty currently exists with respect to the timing, label and regulatory path forward for this compound.  While we believe that AVEED could ultimately be approved and commercialized in the US, we recorded a $65 million, non-cash impairment charge reflecting these heightened uncertainties.  Offsetting this charge is a gain of $125 million, reflecting a reduction in the liability on our balance sheet associated with contingent consideration payable to former Indevus shareholders, under certain circumstances.  The gain reflects our assessment of the decreased probability that we will be obligated to pay this contingent consideration within the specified, two-year contractual timeframe.  

Selected Product Review

PAIN PRODUCTS<
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
(Date:1/23/2015)...  Now available for sale, The Armor1 Ankle Roll Guard is ... sprains by cushioning the ankle from an inversion or ... outside of any shoe type and allows the user ... protection against sprains. With customers in physical therapy, podiatry, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... and NUREMBERG, Germany, April 13, 2012 ... of mobile C-arms presents its award-winning product portfolio ... Together with Xograph ( http://www.xograph.com ), its UK ... vascular specialists, interventional radiologists and cardiologists to provide ...
... ("Unilife" or "Company") (NASDAQ: UNIS ;  ASX: UNS) announced ... fiscal 2012 third quarter ended March 31, 2012 after market trading ... scheduled a conference call for 4:30 p.m. U.S. EDT on Thursday, ... AM AEST) , to review the Company,s financial results, market ...
Cached Medicine Technology:CX 2012: Elevating the Boundaries of Interventional Imaging with Mobile C-arms 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 3
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Nursing (NYUCN) received a two-year, $299,990.00 grant from the ... to research the "Impact of an Internationally Educated Nurse ... Homes." According to the Principal Investigator, Laura Wagner, ... NCSBN,s Patient Safety, Practice (LPN/VN, RN), and International Regulatory ...
... cell therapies hold enormous potential to address some of ... However, the inability to target cells to tissues of ... To address this hurdle, researchers at Brigham and Women,s ... incorporate homing receptors onto the surface of cells. This ...
... THURSDAY, Oct. 27 (HealthDay News) -- A new study warns ... -- or atherosclerosis -- which can lead to heart disease, ... 84 young women, aged 18 to 35, with no known ... blood pressure, high blood cholesterol or family history of premature ...
... Americans need to take action to reduce their risk of ... world dies of a stroke every six seconds and about ... about equivalent to the population of Eugene, Ore. or Savannah, ... Prevention. The agency,s message about stroke prevention comes ahead ...
... Nursing (NYUCN) received a two-year, $452,218.00 grant from ... ""Proinflammatory Biomarkers and Post-Breast Cancer Lymphedema." Post-breast ... and multiple distressing symptoms, is caused by injuries ... advances in cancer treatment lengthen survival, LE has ...
... more cost effective way to provide anesthesia for patients ... a common, often asymptomatic condition that, if not found ... done by investigators at Wake Forest Baptist Medical Center ... anesthesia care (MAC) is better than general anesthesia for ...
Cached Medicine News:Health News:Programming cells to home to specific tissues may enable more effective cell-based therapies 2Health News:Many Young Adults Unaware They're Developing Heart Disease 2Health News:U.S. Health Officials Urge Lifestyle Changes to Cut Stroke Risk 2Health News:NYU College of Nursing receives 450 thousand dollar NIH grant to research post-breast cancer lymphedema 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 3
... EMU36 is a battery-operated digital EEG stand-alone ... signals for epilepsy and other clinical monitoring ... archives these signals through 32 EEG channels ... is a revolutionary monitoring package. The palm-sized ...
... Millennium, the newest entry in the ... experience in epilepsy monitoring with the ... Millennium is a powerful Windows-based digital ... recording and review capabilities that are ...
... a dual output, general purpose stimulator ... Applications extend from single cell to ... channels can be operated independently or ... outputs are non-isolated constant voltage positive ...
... Features 16 R-3 gold-ball electrodes in ... exposed cortex. Each electrode is in ... ease in positioning. Supporting bone clamp ... 8-foot (2.4 m) braided, Teflon-coated wires ...
Medicine Products: